Welcome to our dedicated page for Quantum BioPharma SEC filings (Ticker: QNTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the science and the strategy inside Quantum BioPharma disclosures can feel like decoding two companies at once. The 200-page annual report details proprietary myelin-repair research while dozens of 8-K updates flag shifts in its real-estate-backed investment arm. If you’ve ever asked, “What does Quantum BioPharma report in their SEC filings?” or hunted for a single trial milestone among footnotes, you know the challenge.
Stock Titan solves that problem by pairing real-time EDGAR feeds with AI that translates every section into plain English. Whether you need the Quantum BioPharma quarterly earnings report 10-Q filing or want Quantum BioPharma Form 4 insider transactions real-time, our dashboard highlights the numbers that move the stock. Key documents are linked with short, shareable summaries so Quantum BioPharma SEC filings explained simply stay accurate. You’ll see at a glance how cash from strategic investments funds Phase-2 trials, what the latest Quantum BioPharma 8-K material events explained mean for risk, and how R&D spending trends quarter over quarter.
- AI-powered summaries of 10-K, 10-Q, and 8-K
- Real-time Quantum BioPharma insider trading Form 4 transactions alerts
- Side-by-side financial and R&D trend analysis
- Instant download of all exhibits and XBRL data
Still digging deeper? Activate comparison tools for Quantum BioPharma annual report 10-K simplified, generate a Quantum BioPharma earnings report filing analysis, or set alerts for Quantum BioPharma executive stock transactions Form 4. We also surface voting matters in the Quantum BioPharma proxy statement executive compensation so institutions can model dilution before it happens. By understanding Quantum BioPharma SEC documents with AI, analysts monitor pipeline progress, insider sentiment, and capital allocation—without wading through legalese.
Malone Wealth Ventures LLC filed an Amendment No. 1 to Schedule 13G disclosing its ownership in Quantum Biopharma Ltd. (QNTM) common stock as of 11 June 2025.
- Aggregate beneficial ownership: 689,421 shares, representing 19.9 % of the outstanding class.
- Sole voting power: 109,765 shares (16 % of the firm’s economic stake), indicating limited influence on shareholder votes.
- Sole dispositive power: 689,421 shares; the firm can sell or otherwise dispose of the entire position without third-party consent.
- Shared voting/dispositive power: 0 shares.
- The shares are held in the ordinary course of business; Malone Wealth Ventures certifies it is not seeking to influence control of Quantum Biopharma.
- The filing is made under Rules 13d-1(b), 13d-1(c) and 13d-1(d), affirming the filer’s status as, among other categories, an investment adviser and parent holding company.
- Clients of Malone Wealth Ventures are the economic beneficiaries of the shares, but no individual client holds more than 5 % of the class.
This near-20 % stake makes Malone Wealth Ventures the largest known passive holder of QNTM, signalling meaningful external confidence while keeping governance influence muted due to the relatively low voting power disclosed.
Quantum BioPharma Ltd. (symbol QNTM) filed a routine Form 6-K on 27 June 2025. The filing’s sole purpose is to furnish a press release, dated the same day, as Exhibit 99.1. No financial statements, earnings data, or transaction details are included in this submission. The document confirms the company continues to file its annual report on Form 20-F and bears the signature of Chief Financial Officer Donal Carroll.
Schedule 13D/A (Amendment 3) – Quantum Biopharma Ltd. (QNTM)
Malone Wealth Ventures LLC ("MWV") and its President & CEO Kevin Malone report beneficial ownership of 610,371 common shares, representing 17.8 % of Quantum Biopharma’s outstanding stock. MWV has sole dispositive power over the entire stake and sole voting power over 52,265 shares.
The position was built through (i) open-market purchases using discretionary client funds and (ii) 90,000 shares granted to Kevin Malone for advisory services (30,000 initial grant plus 60,000 continuation grant).
On 23 June 2025, MWV executed 21 exchange transactions, mainly buys between $22.18–$29.19 and one sale of 5,000 shares at $22.549, indicating ongoing accumulation around a volatile price range.
The securities are held for investment purposes; however, Malone’s role as Advisor to the Board means the reporting persons "may be deemed" to seek influence over strategic direction, financing, capitalization and governance. MWV states it may buy or sell additional shares depending on market conditions.
No legal proceedings are disclosed, and both reporting persons are U.S. citizens/entities.
Malone Wealth Ventures LLC has filed a Schedule 13D/A amendment disclosing a 17% ownership stake (580,806 shares) in Quantum Biopharma. The filing reveals significant recent share accumulation through multiple transactions between June 13-20, 2025, with purchase prices ranging from $19.10 to $37.59 per share.
Key details:
- Kevin Malone serves as Advisor to Quantum Biopharma's Board of Directors
- Received 90,000 shares in total as compensation (30,000 initial grant plus 60,000 additional)
- Has sole voting power over 52,265 shares and sole dispositive power over 580,806 shares
- Shares acquired through client funds (Malone Wealth Ventures) and board advisor compensation
The filing indicates potential influence over company control, with Malone participating in discussions regarding strategic direction, financing, capitalization, and corporate governance. The advisory agreement was established on April 15, 2025, with additional RSUs available based on performance goals.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
What is the primary focus of Quantum BioPharma Ltd?
What are the main segments of the company?
How does Quantum BioPharma generate value?
What therapeutic areas does the company target?
How does the company ensure clinical trial integrity?
What distinguishes Quantum BioPharma from its competitors?
Has the company been involved in any legal initiatives?
What role does technology play in its research?
